Sign In
Buy EBS
$7.93
-0.280 (-3.41%)
At Close: Jun 03, 2026
GAITHERSBURG, Md., Sept. 24, 2025 (GLOBE NEWSWIRE) -- In recognition of several observances in September meant to keep the national opioid poisoning epidemic front and center, Emergent BioSolutions In
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
08:34am, Friday, 19'th Sep 2025
GAITHERSBURG, Md., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured new purchase orders from an international government partner for a multi-pro
GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research
GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACA
GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research
GAITHERSBURG, Md., Aug. 29, 2025 (GLOBE NEWSWIRE) -- In honor of International Overdose Awareness Day (IOAD) on August 31, Emergent BioSolutions (NYSE: EBS) is re-launching its Ready to Rescue public
Emergent BioSolutions to Participate in Upcoming Investor Conferences
08:01am, Wednesday, 27'th Aug 2025
GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's senior management team will participate in the following inves
GAITHERSBURG, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- As opioid emergencies continue to be the leading cause of accidental death in the United States,1 Emergent BioSolutions (NYSE: EBS) is teaming up w
Big Rallies Brewing? 3 Analyst Favorites to Watch Closely
09:46am, Monday, 18'th Aug 2025
Companies can receive a big boost on impressive results or promising news, and then it is a matter of maintaining momentum to ensure those gains aren't given back shortly after.
Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally
12:46pm, Tuesday, 12'th Aug 2025
Emergent BioSolutions delivered a strong Q2 2025, beating its own guidance and showing major improvements in margins. EBS has a sound turnaround strategy that is showing signs of success. The company
Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript
07:31pm, Thursday, 07'th Aug 2025
Emergent BioSolutions Inc. (NYSE:EBS ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Joseph C. Papa - CEO, President & Director Richard S.
Emergent BioSolutions Reports Second Quarter 2025 Financial Results
04:15pm, Wednesday, 06'th Aug 2025
GAITHERSBURG, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2025.
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
08:50am, Monday, 28'th Jul 2025
Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovation Ongoing mpox outbreak continues to be a global health threat and is dri
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
08:50am, Monday, 28'th Jul 2025
GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announces its recognition of the U.S. House of Representatives for adding over-the-counter (OTC) nalox
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
07:30am, Tuesday, 15'th Jul 2025
GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, August 6, 2025, at 5:00 pm eastern time to discuss the financial r
